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Abstract
Background: The proportion of older people with advanced dementia who will die in nursing homes is constantly
growing. However, little is known about the dying phase, the type of symptoms, the management of symptoms
and the quality of life and dying in people with advanced dementia. The ZULIDAD (Zurich Life and Death with
Advanced Dementia) study aims at extending the current scientific knowledge by providing first data from Switzerland.
Methods: The ZULIDAD study employs a prospective design to study nursing home residents with advanced dementia
for three years or until their death in eleven nursing homes in Zurich. Observational data from quarterly questionnaires
for relatives and primary nurses is combined with data from the Resident Assessment Instrument – Minimum Data Set
(RAI-MDS). Special focus is put on 1) the cross-sectional analysis of baseline and post-mortem data regarding quality of
life and quality of dying and how the perceptions of these measures differ between relatives and primary nurses, 2) the
longitudinal analyses of established health outcome measures (e.g., EOLD, MSSE, BISAD, QUALID) in order to understand
their trajectories and 3) international comparisons of cross-sectional and longitudinal data.
Discussion: The ZULIDAD study is one of the few existing prospective studies on end-of-life care in dementia and it is
the first prospective study to describe the situation in Switzerland. Its multi-perspective approach allows a comprehensive
approximation to central health outcome measures at the end of life such as pain, suffering or quality of life. Providing
insights into the current provision of care, it can serve as a basis for improving dementia end-of-life care in Switzerland
and internationally.
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Background
In the year 2010, 35 million people were estimated to
live with dementia worldwide and it is predicted that
this number will double every 20 years until 2050 [1].
Even though the percentages differ between countries, the
majority of people with advanced dementia die in long-
term care facilities (67 % in the U.S. [2]; 50.2 % in Wales,
92 % in Netherlands [3]; 30.1 % in Germany [4]). The last
months of life of nursing home residents with advanced
dementia (RAD) are frequently accompanied by distres-
sing symptoms such as dyspnea, pain, pressure ulcers and
eating problems, and these symptoms increase with the
proximity of death [5, 6]. Due to behavioral problems, un-
identified pain, inappropriate medication or other factors,
quality of life can be impaired [7]. Even though there is lit-
tle difference between those people dying with dementia
and those dying without cognitive impairments regarding
burdensome symptoms in the last phase of life [8] and
causes of death [9], RAD are frequently not perceived as
having a terminal condition and mostly do not receive op-
timal palliative care [5, 7, 10]. In order to emphasize the
appropriateness and necessity of palliative care in demen-
tia, the European Association of Palliative Care issued a
white paper which attempts to define high quality pallia-
tive care in dementia [11]. However, only some of the
white paper’s recommendations have been included in na-
tional dementia strategies so far [12].
The increasing amount of studies in the field moti-
vated van der Steen and Goodman [13] to point out
what kind of research is needed in order to advance in
research as well as in practical care regarding dementia
at the end of life. Besides the demand for theory-driven
research, they advocate for study designs which allow for
comparisons either with other patient groups, health
care systems or countries and for analyses of disease tra-
jectories. Furthermore they advocate for multidisciplin-
ary research. The latter is important not only because
palliative care is per se multidisciplinary, but also be-
cause RAD are unable to reliably communicate their
wellbeing, discomfort or care preferences. The conflation
of different proxy estimations, e.g., from relatives (REL),
primary nurses (PN) or physicians regarding central out-
come measures such as pain, suffering, quality of life is es-
sential in order to provide optimal individualized care. So
far, most studies regarding palliative care in dementia have
been small and only few have applied a prospective design
that allows the determination of disease trajectories and the
concomitant proxy estimations [14] (Table 1). Furthermore,
the four published prospective studies often used different
outcome measures in different proxy groups and this ham-
pers the direct comparison of proxy estimations. As a con-
sequence, further multi-perspective prospective studies on
RAD are needed, especially in Switzerland, where data is
completely lacking. Exploratory research adapted to the
Swiss cultural context and the local structures of the health
care system can shed light on the current state of dementia
palliative care in Switzerland. Furthermore, in accordance
with current recommendations on research strategies in
Table 1 Main characteristics of the four published prospective cohort studies on institutional end-of-life care in dementia
Study Sample Data sources Main outcome measures Main study aims
CareAD [25–27] N = 123 (91 cases of death),
census in 3 NH, main inclusion
criteria: life expectancy of 6
month or less, dementia
diagnosis, receiving or
meeting criteria for hospice
or palliative care
Chart review (BL, 3 M, PM);
surrogate decision-makers
(BL, 3 M, PM); physicians
(BL); nurses (BL, incomplete
information); direct assessment
of residents (BL, 3 M)
Medical status (by charts);
treatment decisions (by
surrogates); quality of life
(by caregivers and surrogates);
frequency of contact with
staff (by surrogates); spiritual
and religious beliefs
(by surrogates)
Description of health
problems, examination
of decisions of surrogate
decision-makers
regarding treatment
CASCADE [5, 16] N = 323 (177 cases of
death), main inclusion
criteria: CPS 5 or 6, dementia
diagnosis, GDS = 7
Chart review, nurses and
clinical examination (BL, 3 M,
PM2, PM7); REL (BL, PM2, PM7)
EOLD-SM (by nurses);
EOLD-CAD (by nurses);
EOLD-SWC (by REL);
QUALID (by nurses);
DSI (by REL)
Description of disease
trajectories, resident
comfort, clinical decision-
making, family satisfaction
with care, complicated
grief among REL
DEOLD [17, 28] N = 372 (218 cases of death),
main inclusion criteria: CPS 5
or 6, GDS = 7
Physician (BL, 6 M, PM),
REL (BL, 6 M, PM)
EOLD Scales, PAINAD, QUALID
(by physicians and REL)
Description of comfort,
symptom burden, pain
and family satisfaction
with care
EoLO-PSODEC [29, 30] N = 315 (NH), N= 181 (home
care) (100 cases of death), main
inclusion criteria: FAST≥=7, life
expectancy of more than
two weeks
Chart review (bi-weekly),
nurses (bi-weekly), physicians
(incomplete information)
Diagnosis, ongoing treatment,
current prescriptions, appropriateness
of prescription (by charts), DS-DAT
(by nurses)
Description of treatment
and prescription, discomfort,
critical decisions
Note. Abbreviations: NH nursing home, REL relatives, BL baseline, 3 M three-monthly, 6 M biannually, PM post mortem, PM2 post mortem after two weeks, PM7
post-mortem after 7 weeks, CPS cognitive performance score [15, 31], GDS global deterioration scale [32], EOLD-SM/ -SWC/ -CAD end-of-life in dementia - symptom
management/ -satisfaction with care/-comfort at dying [21], QUALID quality of life in late-stage dementia scale [24], DSI decision satisfaction inventory [33], PAINAD pain
assessment in advanced dementia [34], FAST functional assessment staging [35], DS-DAT discomfort scale for dementia of the alzheimer’s type [36]
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the field [13], for the present study data is prospectively
collected from multiple perspectives. To facilitate com-
parability of data with other countries, the study meth-
odology is closely modeled after existing high-quality
studies. This report presents the methodology estab-
lished in the ZULIDAD study.
Study aims
The aims of the ZULIDAD study are:
1) To describe a sample of Swiss RAD during their last
phase of life and thus explore the situation in
Switzerland (e.g., How are RAD cared for during
the last phase of their life? What are common
symptoms and how are they managed?).
2) To compare the perspectives of REL and PN (e.g.,
What is the level of suffering perceived by REL
and PN? How is the quality of life estimated by
REL and PN?).
3) To describe disease and care trajectories (e.g., How
does care change over time? How do symptoms
change over time?).
4) To compare the results with those from other
studies/countries (e.g., How is the quality of life of
RAD in Switzerland compared to other countries
such as the Netherlands?).
Methods
Study design
The ZULIDAD study employs a prospective multi-
perspective design. Residents of eleven nursing homes
(NH) in the greater Zurich area in Switzerland are followed
for three years or until their death. Observational data is
collected three-monthly through extensive questionnaires
for REL, and PN (see Fig. 1). In addition, routine data from
the Resident Assessment Instrument – Minimal Data Set
(RAI-MDS), Version 2.0 [15], is collected annually (full
assessment) and biannually (abbreviated assessment). In
order to facilitate international comparability, the study de-
sign, inclusion criteria and applied measurements refer to
previous studies, namely CASCADE from U.S. [16], DEOLD
from the Netherlands [17] and Dying Well from Belgium
[18]. ZULIDAD is a collaborative study with partners from
several university centers and departments, nursing homes
and the municipal physician service of Zurich. The conduct
of the ZULIDAD study was approved by the Ethics Com-
mittee of the Canton of Zurich (KEK-ZH-Nr. 2013-0385)
and was registered in FORSbase (Ref No 11530), a Swiss on-
line platform for social science studies.
The ZULIDAD round table
The entire ZULIDAD research process is accompanied
by the Round Table (RT) in terms of a participatory re-
search approach. The RT is composed of representatives
of three relevant stakeholder groups (REL of RAD; pro-
fessionals in dementia care, nursing care and palliative
care; researchers). Scientific and strategic decisions as
well as study results are discussed at the RT on a regular
basis. The RT supervises the ZULIDAD study by support-
ing and advising the research team (e.g., with regard to the
selection of variables, the wording of questions or the ap-
propriate interpretation of results). The RT furthermore
carries out an independent but related project aiming at
the dissemination of the ZULIDAD study results.
Fig. 1 Timeline of data collection in the ZULIDAD study
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Study setting
The ZULIDAD study is a multicenter study. It is being
conducted in eleven NH (ten municipal NH of the City of
Zurich, one privately managed NH specialized in dementia
care, Sonnweid AG). The municipal NH have a predefined
staff ratio, are obliged to have an appropriate skill and
grade mix and are certified on a regular basis. Altogether
the municipal NH encompass 1’625 beds (ranging from 42
to 334). Based on RAI-MDS data 69 % of the residents
had a dementia diagnosis in 2013 (ZULIDAD unpublished
data). The privately run NH Sonnweid offers 154 beds
which are exclusively for people with dementia.
Study population
The ZULIDAD study population comprises three groups of
subjects: 1) RAD, 2) REL, and 3) PN. Eligibility criteria are
presented in Table 2. More than 1’700 RAD were screened,
410 of them met the inclusion criteria and 126 REL and
PN gave their informed consent (as of June 2016). Thus,
the sample size currently encompasses 126 RAD, REL and
PN (3 × 126). The exact sample size will be confirmed in
publications after data collection has finished.
Recruitment and informed consent
Recruitment is conducted consecutively in the eleven par-
ticipating NH. Eligible RAD are identified based on screen-
ing the NH’s RAI-MDS databases on a reference date.
Subsequently, legally authorized representatives (REL and
assistances) and, if the authorized representative cannot be
the informant an additional REL, are contacted by postal
mail which includes an information sheet describing the
study. If they declare interest by returning a prepaid return
form, they receive a phone call by a trained research assist-
ant who provides more information about the study and a
personal meeting is scheduled if interest persists. The first
face-to-face contact with REL includes a detailed clarifica-
tion of the study procedure, provision of written informed
consent (for informant and RAD according to the pre-
sumed will) and – if both consents are provided – the com-
pletion of the baseline questionnaire. A research assistant
then contacts the PN of the RAD directly by telephone (a
general information about the study has been provided by
the manager of the NH in advance), informs about the
study procedure and arranges – if interest is expressed – a
personal meeting in order to provide full study information,
obtain informed consent and to complete the baseline
questionnaire. If REL does not respond to the initial en-
quiry, they receive one postal reminder.
Data collection
After the baseline assessment, questionnaires are sent
three-monthly and are completed autonomously by the
REL and PN (see Fig. 1). If problems occur, participants
are requested to contact the research team. Should a
RAD decease, the last questionnaire (post mortem) is
sent out two weeks (PN) and six weeks (REL), respect-
ively, after death. The duration of the initial face-to-face
meeting is 90-120 min, and the repeated and post mor-
tem questionnaires require 45-60 min to complete. If REL
or PN fail to submit two questionnaires consecutively, they
are excluded from the study. However, unless REL with-
draws consent, the RAD remains in the study population,
as long as either REL or PN continues to submit the ques-
tionnaires. Data collection started in November 2013 and
will presumably end in December 2017.
Instruments
As shown in Table 3, the questionnaires for REL and PN
address several topics suggested by the ZULIDAD RT
members to play an important role in the last phase of life
of RAD. Corresponding variables and instruments were
selected based on clinical and research expertise of the
investigators and existing studies (indicated in Table 3).
Whenever possible, reliable and validated instruments were
used, which were – if necessary – translated into German
(indicated in Table 3) following ISPOR guidelines [19] and/
or slightly adapted to the field of dementia. With few
exceptions, questions have a closed-ended response for-
mat. Overall, there are two sets of ZULIDAD question-
naires, one for REL and one for PN, which in turn
contain three different compositions of variables and
instruments – baseline, three-monthly and post mor-
tem. Questionnaires were revised and piloted by the
members of the ZULIDAD RT. Data is entered into a
central study database which runs on the RedCAP plat-
form [20]. Questionnaire data is complemented by the
routinely collected RAI-MDS data [15].
Table 2 Eligibility criteria for nursing home residents with advanced
dementia, relatives and primary nurses
Inclusion criteria Exclusion criteria
RAD - At least one complete RAI-MDS
assessment in database
- Dementia diagnosis (RAI item
I1q (Alzheimer’s Dementia) or
I1u (other dementia)
- CPS of 5 or 6
- Informed consents by the
authorized representatives,
following the presumed will
of the resident
- Sub-acute or short-term
rehabilitative unit
- Cognitive impairment due
to a major stroke, traumatic
brain injury, tumor, or chronic
psychiatric condition
- Cognitive impairment due
to coma
REL - Informed consent
- Proficiency in German
PN - Informed consent
- Proficiency in German
Note. CPS cognitive performance score, it is composed of five variables from
the RAI-MDS [15], scores range from 0-6. Scores of 4-6 identify residents who
are severely impaired in their daily decision-making. A CPS score of 5 is
comparable to a Mini Mental State Examination score of 5 [37]
Abbreviations: RAD resident with advanced dementia, RAI-MDS resident
assessment instrument – minimum data set, REL relative, PN primary nurse
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Statistical analysis
A first focus will be put on the cross-sectional analysis
of baseline and post-mortem data, regarding quality of
life, quality of dying and comfort/discomfort and how
the perceptions of these measures differ between REL
and PN (see Fig. 2). A second focus will be put on longi-
tudinal analyses in order to understand dynamics of
change and to identify potential factors that influence
stability and deterioration over time. Therefore standard
longitudinal data analysis approaches based on the gen-
eral linear model and multilevel and structural equation
models such as latent growth curve or growth mixture
models will be applied. In line with previous publications
established scales such as EOLD [21], MSSE [22], BISAD
[23] or QUALID [24] will be used as primary outcome
measures to estimate quality of dying. A third focus will
be put on the comparisons with data from other coun-
tries, e.g., the Netherlands.
Discussion
The importance of dementia as a life-limiting condition is
increasing. As a consequence, providing end-of-life care in
dementia will become one of the most challenging tasks
Table 3 Data collection elements in the ZULIDAD study
Topic Instruments Source Time
RAD characteristics
Demographics REL BL
Dementia REL/RAI-MDS BL
Health status REL/PN/RAI-MDS BL/6M
Quality of life QUALIDabcd,
single item
REL/PN BL/3M/PM
Pain BISAD,
single item
PN BL/3M/PM
Suffering MSSEa,
single item
PN BL/3M/PM
Behavioral problems NPI-Q PN BL/3M/PM
Survival time REL/PN BL/3M
Care
Treatment strategy PN BL/3M/PM
Current treatments PN BL/3M/PM
Symptom
Management
EOLD-SMabc REL/PN BL/3M/PM
Satisfaction with care EOLD-SWCabc,
single item,
open question
REL BL/3M/PM
Communication REL/PN BL/3M/PM
Trust in staff REL BL/3M/PM
Decisions DSIab REL 3M/PM
Dying
Circumstances
of dying
REL/PN PM
Quality of dying EOLD-CADabcd,
QOD-LTCa,
QODD, FPCSa,
single item
REL/PN PM
Advanced planning issues
Advanced directives REL/PN BL/PM
Presumed preferences PADDa REL BL
Care agreements PN BL/3M/PM
REL characteristics
Demographics REL BL
Wellbeing WHO-5 REL BL/3M/PM
Relation to RAD REL BL/3M
Knowledge REL BL
Attitudes REL BL/3M/PM
PN characteristics
Demographics PN BL
Wellbeing WHO-5 PN BL/3M/PM
Table 3 Data collection elements in the ZULIDAD study
(Continued)
Work PN BL/3M/PM
Attitudes PN BL/3M/PM
Note. RAD Demographics = Sex, year of birth, religious affiliation, marital status.
Dementia = Dementia type, Cognitive Performance Scale. Health status = Overall
health status, changes in overall health status, RAI-MDS. Survival time = Estimated
survival time, has dying phase started? Treatment strategy = palliative vs. curative.
Current treatments =Medical treatments, safety-related measures, psychosocial
interventions. Communication = Frequency of and satisfaction with staff/REL
communication. Trust in staff = Trust in nursing staff. Decisions = Satisfaction with
decisions (DSI), discussions about interventions and whether they lead to
decisions. Circumstances of Dying = Cause of death, place of death, attendees,
subjective estimation of global dying quality. Quality of dying = REL: EOLD-CAD,
QOD-LTC, FPCS; PN: EOLD-CAD. Advanced directives = Availability, content, were
directives adhered to? Care agreements = Regarding medical treatments and
safety-related measures. Demographics REL = Sex, year of birth, nationality,
religious affiliation, education. Wellbeing REL = Health status, wellbeing (WHO-5),
quality of life, emotional burden, feelings of guilt. Relation to RAD = relationship
quality before dementia and after dementia, frequency and duration of visits.
Knowledge = Knowledge of dementia, palliative care and new legislation.
Attitudes = Attitudes towards means of ending or prolonging life.
Demographics PN = Sex, year of birth. Wellbeing PN= Health status, wellbeing
(WHO-5), quality of life. Work =Work satisfaction, work load, work
experiences, qualification
Abbreviations: RAD resident with advanced dementia, RAI-MDS resident
assessment instrument – minimum data set, REL relative, BL baseline
questionnaire, 3 M three-monthly questionnaire, 6 M six-monthly RAI-MDS, PM
post mortem questionnaire, QUALID quality of life in late-stage dementia scale
[24], BISAD Observational instrument to assess pain in dementia [23], MSSE
mini suffering state examination [22], EOLD-SM/ -SWC/ -CAD end-of-life care in
dementia – symptom management/ -satisfaction with care/ -comfort assessment
in dying [21], QOD-LTC quality of dying in long-term care [38], PADD preferences
about dying and death [39], QODD quality of dying and death (corresponds with
PADD) [40], FPCS family perception of care scale [41], DSI decision satisfaction
inventory [33], WHO-5 the WHO-five well-being index [42]
anewly translated into German, bapplied in CASCADE study, capplied in DEOLD
study, dapplied in the “Dying Well” study
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for health care systems. Yet, existing knowledge about pal-
liative care in dementia is scarce. With a prospective co-
hort design the ZULIDAD study examines the last phase
of life of RAD. It is one of the few existing prospective
studies on the last phase of life in dementia and it is the
first prospective study to describe the situation in the
greater Zurich area, Switzerland. The combination of data
from REL, PN and RAI-MDS allows a comprehensive de-
scription and an approximation to the actual quality of life
and quality of dying of the RAD. Furthermore, the multi-
perspective approach will help to close knowledge gaps
regarding differences in REL’s and PN’s perceptions of cen-
tral outcome measures at the end of life in dementia. Sys-
tematic differences in proxy estimations (e.g., REL and
PN) can provide a basis for interventions and interven-
tional studies aiming at optimizing palliative care.
The alignment of the ZULDAD study design, inclusion
criteria and applied measures to related studies allows for
comparisons between European countries and between
Europe and U.S. However, due to the geographical limita-
tion to the greater Zurich area and the limitation to muni-
cipal NH and NH specialized in dementia care the study
results will neither be generalizable to the French- and
Italian-speaking parts of Switzerland nor to all nursing
homes in Zurich. The right-censoring of some of the data
(because not all RAD will be followed until death) is an-
other bias that needs to be considered when interpreting
the data. A unique characteristic of the ZULIDAD study is
that it is performed as participatory research project
with stakeholder involvement throughout the entire
study process. The ZULIDAD RT promotes the prac-
tical relevance and the effective knowledge transfer of
study results.
In conclusion, the ZULIDAD study provides prospect-
ive multi-perspective data on the last phase of life of
RAD. This is an important pre-requisite to improve pal-
liative care in advanced dementia in Switzerland and
internationally.
Fig. 2 Illustration of proposed data analyses
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